GLP-1 & Incretin Science

When the Reason for Treatment Causes the Outcome

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Confounding by indication occurs when the condition prompting treatment, rather than the treatment, causes the outcome observed. A 2026 Danish nationwide cohort demonstrates it directly: the same drugs showed an association in one indication and not in another.

Key facts

Problem
The reason for treatment causes the outcome
Affects
All observational drug studies
Not fixed by
Adjusting for measured confounders alone
Worked example
Hviid 2026 (PMID 41852577)
The tell
Association in one indication, not another
Randomisation
The only complete solution

What the problem actually is

People who receive a medicine differ from people who do not, and the most important way they differ is that they had a condition warranting it. If that condition also affects the outcome being studied, an association between drug and outcome appears even when the drug does nothing. The confounder is the indication itself.

Why it is harder to handle than ordinary confounding

Age or sex can be measured and adjusted for. The severity and duration of the condition that prompted prescribing often cannot be captured fully in registry data, and the residual is the part most strongly related to both treatment and outcome. Statistical adjustment reduces the problem without eliminating it.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The 2026 study that shows it clearly

Hviid and colleagues examined periconceptional GLP-1 receptor agonist exposure and obstetric outcomes in Danish health registries covering October 2009 to December 2023. Preterm birth risk was raised where the drugs were used for diabetes (liraglutide adjusted odds ratio 1.70, 95% confidence interval 1.17 to 2.48; semaglutide 1.84, 1.24 to 2.7), but not where they were used for weight management.

Why that pattern is the informative part

Same drugs, same registry, same outcome, same period. The only thing differing between the two groups is why the drug was prescribed. If the medicine were causing preterm birth it should do so regardless of indication. That it did not is strong evidence the association tracks the underlying diabetes, and the authors state that conclusion themselves.

Why this is a model for reading any observational drug study

Comparing across indications is a natural experiment built into the data. Where a study can show that an association holds in one indication and not another, it has tested its own confounding rather than merely adjusting for it. Most observational studies cannot do this, and it deserves attention when one can.

How coverage typically gets this wrong

By reporting the headline association and omitting the split. A summary saying these drugs are linked to preterm birth would be technically defensible and would invert the study's actual conclusion, which is that the medication is probably not the causal factor. The finding is in the comparison, not the association.

Frequently asked questions

What is confounding by indication?

When the condition that prompted treatment, rather than the treatment itself, causes the outcome observed, making a drug appear responsible when it is not.

Can it be adjusted away?

Not fully. Severity and duration of the underlying condition are often incompletely captured, and that residual is what matters most.

How did the 2026 study demonstrate it?

The same drugs showed raised preterm birth risk in the diabetes indication but not the weight-management one, so the association tracks the indication.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.